Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
BURLINGTON, Mass. , June 18, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO Capital Markets 2019 Prescriptions for Success Healthcare
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , June 07, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 10 new employees consisting of an aggregate of 25,250 stock options and 4,350 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis
BURLINGTON, Mass. , June 05, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent number 10,301,645 for FX201, the company's gene therapy product candidate.
View HTML
Toggle Summary Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
BURLINGTON, Mass. , May 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2019 RBC Capital Markets Global Healthcare Conference in New York
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Pooled analysis published in Pain and Therapy indicated that the number of rescue medication tablets used per day through Week 24 was significantly less for ZILRETTA versus placebo and triamcinolone acetonide crystalline suspension (TAcs) Reduced rescue medication use further supports the analgesic
View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights
Company reported ZILRETTA ®  ( triamcinolone acetonide extended-release injectable suspension) net sales of $10.6 million in first quarter 2019 Preliminary ZILRETTA net sales for April 2019 were approximately $5.1 million   Flexion reaffirms full-year 2019 revenue guidance of $65-$80 million  
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , May 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of an aggregate of 7,600 stock options and 1,250 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International (OARSI) World Congress
Repeat Administration of Triamcinolone Acetonide Extended-Release Affords Consistent , Clinically Relevant Improvements in Pain: Results from a Phase 3b, Single-Arm, Open-Label Study (Poster 732) Safety and Systemic Exposure of Triamcinolone Acetonide Following Intra-Articular Injection of
View HTML
Toggle Summary Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019
BURLINGTON, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, May 8, 2019 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Post-hoc analysis published in Advances in Therapy indicated patients with unilateral knee osteoarthritis experienced significant and durable reductions in pain with ZILRETTA vs. immediate-release triamcinolone acetonide Patients in ZILRETTA arm experienced profound magnitude of analgesic effect
View HTML